Drug Trial Radar · NCT05039216
Biobank for Inflammatory Chronic Diseases and Osteoporosis
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Sep 13, 2021
Primary completion
Sep 2, 2026
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Spondyloarthritis
- Osteoporosis
Interventions
Blood samplingBiological
4 tubes of 7 mL will be sampled
Primary outcomes
What the sponsor says the trial is designed to measure.
- EULAR response after 3 monthsTime frame: after 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Purpan University Hospital
Toulouse, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.